Pricing and Welfare Implications of Parallel Imports in the Pharmaceutical Industry

  • Izabela Jelovac
  • Catalina Bordoy


In this paper we investigate the implications of permitting parallel imports of pharmaceuticals produced by a monopoly, from one country to another. We use a model where countries differ in the patients’ level of co-payment for buying pharmaceuticals, and patients differ in the utility obtained from the consumption of pharmaceuticals. We show that the effects of parallel imports on total welfare are as follows: On the one hand, when countries differ in their health system only, parallel imports decrease total welfare; On the other hand, when countries differ in the health needs of their patients only, parallel imports enhance total welfare.

parallel imports welfare 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Danzon, P. M. (1998). “The Economics of Parallel Trade.”PharmacoEconomics 13(3), 293–304.Google Scholar
  2. Ganslandt, M. and K. E. Maskus. (2001). “Parallel Imports ofPharmaceutical Products in the European Union.”Working paper No. 546. The research institute of industrial economics (Stockholm).Google Scholar
  3. Hausman, J. A. and J. K. MacKie-Mason (1988). “Price Discrimination and Patent Policy.”RAND Journal of Economics19(2), 253–265.Google Scholar
  4. Jelovac, I (2002). “On the Relationship Between the Negotiated Prices of Pharmaceuticals and the Patients’ Co-Payment.”Working paper 0208. Center for Economic Development. Hong Kong University of Science and Technology.Google Scholar
  5. Jelovac, I (2004). “Monopolistic Third-Degree Price Discrimination of Subsidized Goods.”Mimeo.Google Scholar
  6. Malueg, D. A. and M. Schwartz (1994). “Parallel Imports, Demand Dispersion, and International Price Discrimination.”Journal of International Economics 37, 167–195.Google Scholar
  7. Maskus, K. E (2000). “Parallel Imports.”World Economy 23(9), 1269–1284.Google Scholar
  8. Maskus, K. E (2001). “Parallel Imports in Pharmaceuticals: Implications for Competition and Prices in Developing Countries.”Final Report to the World Intellectual Property Organization.Google Scholar
  9. Maskus, K. E. and Y. Chen (2002). “Parallel Imports in a Model of Vertical Distribution: Theory, Evidence and Policy.”Pacific Economic Review 7(2), 319–334.Google Scholar
  10. Pavcnik, N (2002). “Do Pharmaceutical Prices Respond to Potential Patient Out-of-Pocket Expenses?”RAND Journal Economics 33(3), 469–487.Google Scholar
  11. Pecorino, P (2002). “Should the US Allow Prescription Drug Reimports from Canada?”Journal of Health Economics 796, 1–10.Google Scholar
  12. Richardson, M (2002). “An Elementary Proposition Concerning Parallel Imports.”Journal of International Economics 56, 233–245.Google Scholar
  13. Robinson, J (1933). Economics of Imperfect Competition. London: Macmillan.Google Scholar
  14. Schmalensee, R (1981). “Output and Welfare Implications of Monopolistic Third-Degree Price Discrimination.”American Economic Review 71, 242–247.Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  1. 1.CREPP—University of LiegeBelgium
  2. 2.MERITMaastricht UniversityThe Netherlands
  3. 3.CREPP—University of LiegeLiegeBelgium

Personalised recommendations